Access the full text.
Sign up today, get DeepDyve free for 14 days.
K. Schalper, E. Kaftan, R. Herbst (2016)
Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for ResearchClinical Cancer Research, 22
S. Antonia, J. López-Martín, J. Bendell, P. Ott, Matthew Taylor, J. Eder, D. Jäger, C. Pietanza, D. Le, F. Braud, M. Morse, P. Ascierto, L. Horn, A. Amin, R. Pillai, J. Evans, I. Chau, P. Bono, A. Atmaca, P. Sharma, C. Harbison, Chen-Sheng Lin, O. Christensen, E. Calvo (2016)
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.The Lancet. Oncology, 17 7
J. Brahmer (2012)
PD-1-targeted immunotherapy: recent clinical findings.Clinical advances in hematology & oncology : H&O, 10 10
R. Herbst, P. Baas, Dong-Wan Kim, E. Felip, J. Pérez-Gracia, Ji-Youn Han, J. Molina, Joo‐Hang Kim, C. Arvis, M. Ahn, M. Majem, M. Fidler, G. Castro, M. Garrido, G. Lubiniecki, Shentu Yue, E. Im, M. Dolled-Filhart, E. Garon (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 387
F. Passiglia, G. Bronte, V. Bazan, C. Natoli, S. Rizzo, A. Galvano, A. Listì, G. Cicero, C. Rolfo, D. Santini, A. Russo (2016)
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysisOncotarget, 7
L. Sholl, D. Aisner, T. Allen, M. Beasley, A. Borczuk, P. Cagle, V. Capelozzi, S. Dacic, L. Hariri, K. Kerr, S. Lantuejoul, M. Mino‐Kenudson, Kirtee Raparia, N. Rekhtman, S. Roy-Chowdhuri, E. Thunnissen, M. Tsao, Y. Yatabe (2016)
Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.Archives of pathology & laboratory medicine, 140 4
K. Kerr, F. Hirsch (2016)
Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?Archives of pathology & laboratory medicine, 140 4
N. Rizvi, J. Mazières, D. Planchard, T. Stinchcombe, G. Dy, S. Antonia, L. Horn, H. Léna, E. Minenza, B. Mennecier, G. Otterson, L. Campos, D. Gandara, B. Levy, S. Nair, G. Zalcman, J. Wolf, P. Souquet, E. Baldini, F. Cappuzzo, C. Chouaid, A. Dowlati, R. Sanborn, A. López-Chávez, C. Grohé, R. Huber, C. Harbison, C. Baudelet, B. Lestini, S. Ramalingam (2015)
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.The Lancet. Oncology, 16 3
A. Scheel, M. Dietel, L. Heukamp, K. Jöhrens, T. Kirchner, S. Reu, J. Rüschoff, H. Schildhaus, P. Schirmacher, M. Tiemann, A. Warth, W. Weichert, R. Fischer, J. Wolf, R. Buettner (2016)
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomasModern Pathology, 29
M. Sznol, Lieping Chen (2013)
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—ResponseClinical Cancer Research, 19
K. Kerr, M. Tsao, A. Nicholson, Y. Yatabe, I. Wistuba, F. Hirsch (2015)
Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 10 7
Roy Herbst, J. Soria, M. Kowanetz, G. Fine, O. Hamid, M. Gordon, Jeffery Sosman, David McDermott, J. Powderly, S. Gettinger, H. Kohrt, L. Horn, Donald Lawrence, S. Rost, M. Leabman, Yuanyuan Xiao, A. Mokatrin, H. Koeppen, P. Hegde, I. Mellman, Daniel Chen, F. Hodi (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature, 515
E. Garon, N. Rizvi, R. Hui, N. Leighl, A. Balmanoukian, J. Eder, A. Patnaik, C. Aggarwal, M. Gubens, L. Horn, E. Carcereny, M. Ahn, E. Felip, Jong-Seok Lee, M. Hellmann, O. Hamid, J. Goldman, J. Soria, M. Dolled-Filhart, R. Rutledge, Jin Zhang, J. Lunceford, Reshma Rangwala, G. Lubiniecki, C. Roach, K. Emancipator, L. Gandhi (2015)
Pembrolizumab for the treatment of non-small-cell lung cancer.The New England journal of medicine, 372 21
J. Brahmer (2013)
Harnessing the immune system for the treatment of non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 8
M. Lawrence, P. Stojanov, P. Polak, G. Kryukov, K. Cibulskis, A. Sivachenko, S. Carter, C. Stewart, C. Mermel, S. Roberts, Adam Kiezun, P. Hammerman, A. McKenna, Y. Drier, L. Zou, A. Ramos, Trevor Pugh, Nicolas Stransky, E. Helman, Jaegil Kim, C. Sougnez, L. Ambrogio, E. Nickerson, Erica Shefler, M. Cortés, D. Auclair, G. Saksena, Douglas Voet, M. Noble, D. Dicara, Pei Lin, Lee Lichtenstein, David Heiman, T. Fennell, M. Imieliński, Bryan Hernandez, Eran Hodis, S. Baca, A. Dulak, Jens Lohr, D. Landau, Catherine Wu, J. Meléndez-Zajgla, A. Hidalgo-Miranda, A. Koren, S. Mccarroll, J. Mora, B. Crompton, R. Onofrio, Melissa Parkin, W. Winckler, K. Ardlie, S. Gabriel, C. Roberts, J. Biegel, K. Stegmaier, A. Bass, L. Garraway, M. Meyerson, T. Golub, D. Gordenin, S. Sunyaev, E. Lander, G. Getz (2014)
Mutational heterogeneity in cancer and the search for new cancer genes
K. Kerr, M. Nicolson (2016)
Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.Archives of pathology & laboratory medicine, 140 3
C. Massard, M. Gordon, Sunil Sharma, S. Rafii, Z. Wainberg, J. Luke, T. Curiel, G. Colón-Otero, O. Hamid, R. Sanborn, P. O’Donnell, A. Drakaki, W. Tan, J. Kurland, M. Rebelatto, Xiaoping Jin, J. Blake-Haskins, A. Gupta, N. Segal (2016)
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 26
J. Hamanishi, M. Mandai, N. Matsumura, K. Abiko, T. Baba, I. Konishi (2016)
PD-1/PD-L1 blockade in cancer treatment: perspectives and issuesInternational Journal of Clinical Oncology, 21
A. Warth, T. Muley, M. Meister, W. Weichert (2015)
Preanalytics in lung cancer.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 199
N. Rizvi, M. Hellmann, J. Brahmer, R. Juergens, H. Borghaei, S. Gettinger, L. Chow, D. Gerber, S. Laurie, J. Goldman, F. Shepherd, Allen Chen, Yun Shen, F. Nathan, C. Harbison, S. Antonia (2016)
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 25
S. Topalian, F. Hodi, J. Brahmer, S. Gettinger, David Smith, David McDermott, J. Powderly, Richard Carvajal, J. Sosman, M. Atkins, P. Leming, D. Spigel, S. Antonia, L. Horn, Charles Drake, D. Pardoll, Lieping Chen, W. Sharfman, Robert Anders, J. Taube, T. McMiller, Haiying Xu, A. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G. Kollia, A. Gupta, J. Wigginton, M. Sznol (2012)
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.The New England journal of medicine, 366 26
G. Bussolati, L. Annaratone, F. Maletta (2015)
The pre-analytical phase in surgical pathology.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 199
L. Fehrenbacher, A. Spira, M. Ballinger, M. Kowanetz, J. Vansteenkiste, J. Mazières, Keunchil Park, David Smith, A. Artal-Cortes, C. Lewanski, F. Braiteh, D. Waterkamp, P. He, W. Zou, Daniel Chen, J. Yi, A. Sandler, A. Rittmeyer (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialThe Lancet, 387
M. Sznol, Lieping Chen (2013)
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human CancerClinical Cancer Research, 19
B. Vogelstein, N. Papadopoulos, V. Velculescu, Shibin Zhou, L. Diaz, K. Kinzler (2013)
Cancer Genome LandscapesScience, 339
H. Borghaei, L. Paz-Ares, L. Horn, D. Spigel, M. Steins, N. Ready, L. Chow, E. Vokes, E. Felip, E. Holgado, F. Barlesi, M. Kohlhäufl, O. Arrieta, M. Burgio, J. Fayette, H. Léna, E. Poddubskaya, D. Gerber, S. Gettinger, C. Rudin, N. Rizvi, L. Crinò, G. Blumenschein, S. Antonia, C. Dorange, C. Harbison, F. Finckenstein, J. Brahmer (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.The New England journal of medicine, 373 17
J. Brahmer, K. Reckamp, P. Baas, L. Crinò, W. Eberhardt, E. Poddubskaya, S. Antonia, A. Płużański, E. Vokes, E. Holgado, D. Waterhouse, N. Ready, J. Gainor, O. Frontera, L. Havel, M. Steins, M. Garassino, J. Aerts, M. Dómine, L. Paz-Ares, M. Reck, C. Baudelet, C. Harbison, B. Lestini, D. Spigel (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.The New England journal of medicine, 373 2
S. Gettinger, N. Rizvi, L. Chow, H. Borghaei, J. Brahmer, N. Ready, D. Gerber, F. Shepherd, S. Antonia, J. Goldman, R. Juergens, S. Laurie, F. Nathan, Yun Shen, C. Harbison, M. Hellmann (2016)
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 25
M. Teng, S. Ngiow, A. Ribas, M. Smyth (2015)
Classifying Cancers Based on T-cell Infiltration and PD-L1.Cancer research, 75 11
S. Gettinger, L. Horn, L. Gandhi, D. Spigel, S. Antonia, N. Rizvi, J. Powderly, R. Heist, R. Carvajal, D. Jackman, L. Sequist, David Smith, P. Leming, D. Carbone, M. Pinder-Schenck, S. Topalian, F. Hodi, J. Sosman, M. Sznol, D. McDermott, D. Pardoll, V. Sankar, C. Ahlers, M. Salvati, J. Wigginton, M. Hellmann, G. Kollia, A. Gupta, J. Brahmer (2015)
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 18
F. Hirsch, P. Bunn, R. Herbst (2014)
“Companion Diagnostics”: Has Their Time Come and Gone?Clinical Cancer Research, 20
MS Lawrence, P Stojanov, P Polak (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genesNature, 499
Tumours with high somatic mutation rates escape immune surveillance by upregulating receptors and ligands such as programmed death receptor-1 and its ligand (PD-1/PD-L1). Checkpoint inhibitors (ICI) provide encouraging therapeutic results in non-small cell lung cancers (NSCLC) and may soon be used in 2nd or 1st line therapy. Currently PD-L1 immunohistochemistry (IHC) expression assessed on tumour cells is used as a predictive biomarker, since better patient outcomes are often, but not always associated with increased tumour cell PD-L1 IHC expression. However pre-analytical variables, different anti-PD-L1 clones used on different staining platforms, different specimens types, as well as intra- and interobserver variability influence the results. We will only understand PD-L1 expression on tumour cells if we accept that PD-L1 is an inducible pathophysiological factor with variable levels of PD-L1 expression depending on the immunological status. Should we test PD-L1 during initial diagnostic work up before, or at the point when immune checkpoint therapy is considered? Taking all arguments into account the value of PD-L1 as a predictive biomarker is questionable. Other predictive biomarkers such as high mutation burden, mRNA expression, neo-antigens and the diversity of tumour antigen-specific T cells should be evaluated in the future. Here we review results presented in 30 journal articles and three reviews covering this topic in the last 3 years.
memo - Magazine of European Medical Oncology – Springer Journals
Published: Oct 28, 2016
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.